{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=13&state=Colorado", "query": { "state": "Colorado", "city": "Aurora", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 7434, "total_pages": 744, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=14&state=Colorado&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Aurora&page=12&state=Colorado&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T13:01:33.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00986154", "title": "Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Thromboembolism", "Venous Thrombosis" ], "interventions": [ { "name": "edoxaban tosylate(DU-176b)", "type": "DRUG" }, { "name": "low molecular weight heparin/unfractionated heparin", "type": "DRUG" }, { "name": "warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8292, "start_date": "2009-10", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 82, "location_summary": "Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00986154" }, { "nct_id": "NCT05814666", "title": "Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HNSCC" ], "interventions": [ { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Flamingo Therapeutics NV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2023-05-30", "completion_date": "2025-08-14", "has_results": true, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 21, "location_summary": "Tucson, Arizona • Irvine, California • Torrance, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Westwood, Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05814666" }, { "nct_id": "NCT02979522", "title": "A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 59, "start_date": "2017-09-06", "completion_date": "2029-09-24", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 2, "location_summary": "Aurora, Colorado • Cincinnati, Ohio", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02979522" }, { "nct_id": "NCT01577173", "title": "A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "MEHD7945A", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2012-07", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 14, "location_summary": "Stanford, California • Aurora, Colorado • Miami, Florida + 10 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Paducah", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01577173" }, { "nct_id": "NCT00402246", "title": "CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Arrhythmia", "Tachycardia", "Atrial Fibrillation", "Ventricular Fibrillation" ], "interventions": [ { "name": "Remote Management", "type": "OTHER" }, { "name": "In-Office Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Medtronic Cardiac Rhythm and Heart Failure", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2009, "start_date": "2006-11", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2011-02-25", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 127, "location_summary": "Mobile, Alabama • Mesa, Arizona • Scottsdale, Arizona + 124 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402246" }, { "nct_id": "NCT01713946", "title": "A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberous Sclerosis Complex-associated Refractory Seizures" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antiepileptic drug (1 to 3 only)", "type": "DRUG" }, { "name": "open label RAD001 (only used for post-extension phase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 366, "start_date": "2013-04-29", "completion_date": "2017-10-25", "has_results": true, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01713946" }, { "nct_id": "NCT03931941", "title": "Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clostridium Difficile Infection", "Infection", "Communicable Diseases" ], "interventions": [ { "name": "RBX2660", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rebiotix Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 793, "start_date": "2019-07-30", "completion_date": "2023-07-21", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 46, "location_summary": "Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Oxnard", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hamden", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03931941" }, { "nct_id": "NCT06191094", "title": "Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Retinopathy", "Vitreous Hemorrhage Due to Diabetes Mellitus" ], "interventions": [ { "name": "Faricimab Injection", "type": "DRUG" }, { "name": "sham treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-07-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06191094" }, { "nct_id": "NCT01885559", "title": "HALT Progression of Polycystic Kidney Disease Study B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney, Polycystic" ], "interventions": [ { "name": "Lisinopril", "type": "DRUG" }, { "name": "Telmisartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "15 Years to 64 Years" }, "enrollment_count": 486, "start_date": "2006-01", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2020-04-22", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 7, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01885559" }, { "nct_id": "NCT00660959", "title": "Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyponatremia With Normal Extracellular Fluid Volume" ], "interventions": [ { "name": "lixivaptan", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CardioKine Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2008-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-06-28", "last_synced_at": "2026-11-02T13:01:33.584Z", "location_count": 38, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00660959" } ] }